Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review)

Targeted therapy with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is a standard modality of the 1st-line treatments for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), and substantially improves their prognosis. However, EGFR T790M mutation is th...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Jingyi, Huang, Zhengrong, Han, Linzhi, Gong, Yan, Xie, Conghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562388/
https://www.ncbi.nlm.nih.gov/pubmed/34558640
http://dx.doi.org/10.3892/ijo.2021.5270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562388/
https://www.ncbi.nlm.nih.gov/pubmed/34558640
http://dx.doi.org/10.3892/ijo.2021.5270

Ejemplares similares